If future longitudinal assessments of converters confirm this NfL increase with proximity to ataxia onset (i.e. NfL as proximity/preconversion stratification biomarker), NfL might aid the selection of preataxic candidate subjects for therapeutic intervention, as invasive treatments (like ASOs) should likely be applied neither unnecessarily early nor too late in preataxic SCA3 subjects. This evidence concerns the gene NEFL and Ataxia.